Panobinostat is used in combination with the anti-cancer drug bortezomib and the corticoid dexamethasone for the treatment of multiple myeloma in adults who had received at least two previous treatments, including bortezomib and an immunomodulatory agent.
Please fill in the details about your medicine requirement on this form.
60/4, T&T House. Yusuf Sarai.
New Delhi:110016 India.
Panobinostat (trade name Farydak) is a drug by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).
On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma,] and on 28 August 2015 it was approved by the European Medicines Agency for the same use.
Global Pharma Network can help you to provide access of Panobinostat medications sold under the brand name for Multiple Myeloma treatment by connecting Patients, Health Care Centers, Pharmacies and Retail Outlets with approved supplier, exporter and distributor of Generic drugs, innovator brands and biosimilar medicines from India. Call Mr. Tarun at +91 8744044044 for more details.
The Global Pharma Network is not an online pharmacy company but we help patient to connect with suppliers in the delivering of Multiple Myeloma medications a pharmaceutical drug (prescription drug, prescription medication or prescription medicine) that legally requires a medical prescription to be dispensed in following countries as per the customer's prescribed medication and applicable regulatory approval.
International: Epclusa, Harvoni, Vosevi Indian Manaufacturer Brands: Hepcinat (Natco Pharma Ltd.) / Hepcvir (Cipla Limited) / Resof (Hetero Drugs Ltd ) / SoviHep (Zydus Cadila)
Global Pharma Network will help you in importing and exporting this medicine only upon the valid prescription of a licensed medical practitioner and other documents as required by the laws of the jurisdiction in which you are present. USA, UK, Russia, China, India, Nepal, Bhutan, Myanmar / Burma, Laos, Thailand, Cambodia, Hong Kong, Macau, Malaysia, Indonesia, Middle East, Japan, Philippines.